Signal Transducer and Activator of Transcription 3 (Stat3C) Promotes Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Lung Tumorigenesis-Reference-Cited by-同舟云学术

Signal Transducer and Activator of Transcription 3 (Stat3C) Promotes Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Lung Tumorigenesis

Published:2011-10 Issue:4 Volume:179 Page:2131-2141
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Wu Lingyan,Du Hong,Li Yuan,Qu Peng,Yan Cong

Funder

NIH

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference33 articles.

1. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung;Li;Cancer Res,2007

2. Matrix metalloproteinase 12 overexpression in lung epithelial cells plays a key role in emphysema to lung bronchioalveolar adenocarcinoma transition;Qu;Cancer Res,2009

3. Myeloid-specific expression of Api6/AIM/Sp alpha induces systemic inflammation and adenocarcinoma in the lung;Qu;J Immunol,2009

4. Qu P, Yan C, Du H: Matrix metalloproteinase 12 overexpression in myeloid lineage cells plays a key role in modulating myelopoiesis, immune suppression, and lung tumorigenesis. Blood 117:4476–4489

5. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease;Qu;Lung Cancer,2009

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulation: A new approach to cancer cachexia, potentially suitable for aging;Molecular Aspects of Medicine;2024-12

2. The JAK-STAT signaling-related signature serves as a prognostic and predictive biomarker for renal cell carcinoma immunotherapy;Gene;2024-11

3. The immunosuppressive landscape in tumor microenvironment;Immunologic Research;2024-05-01

4. Epigenetic regulation and therapeutic targets in the tumor microenvironment;Molecular Biomedicine;2023-06-05

5. Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC;Cancers;2023-01-06